The Science

Mechanism of Action

BPC-157 is a pentadecapeptide derived from a protective protein found in gastric juice. It upregulates growth hormone receptor expression in tendon fibroblasts, accelerates angiogenesis via VEGF pathway activation, and modulates nitric oxide synthesis to reduce inflammation at injury sites. It also demonstrates cytoprotective effects on the gut lining, making it uniquely effective for athletes with high training loads and associated GI stress.

Research Summary

Over 80 preclinical studies document BPC-157's regenerative effects across tendon, ligament, muscle, bone, and neural tissue. Human case series and clinical observations consistently report accelerated recovery from soft tissue injuries, reduced pain, and improved joint function. No serious adverse events have been reported in published literature at therapeutic doses.

Mechanism of Action

TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring peptide present in virtually all human cells. Its primary mechanism is actin sequestration — it binds G-actin monomers, regulating cytoskeletal dynamics and enabling rapid cell migration to injury sites. It also upregulates cell surface receptors for growth factors, promotes angiogenesis, and reduces fibrous scar tissue formation, resulting in higher-quality tissue repair compared to natural healing.

Research Summary

Thymosin Beta-4 has been studied in Phase I and Phase II clinical trials for cardiac repair and wound healing. TB-500 (the synthetic analog) has an extensive preclinical literature demonstrating systemic recovery acceleration, reduced fibrosis, and improved flexibility. The combination of BPC-157 and TB-500 is considered the most studied peptide stack for musculoskeletal recovery.

Mechanism of Action

Recombinant human growth hormone (somatropin) is bioidentical to endogenous GH produced by the anterior pituitary. It binds GH receptors in liver, muscle, and adipose tissue, stimulating IGF-1 production — the primary downstream mediator of anabolic effects. IGF-1 drives protein synthesis in skeletal muscle, inhibits lipolysis in adipocytes, and promotes nitrogen retention. Exogenous HGH bypasses pituitary variability and age-related GH decline, delivering a calibrated anabolic signal at a consistent dose.

Research Summary

HGH has one of the most extensive clinical research profiles of any peptide hormone, with decades of data from GH deficiency treatment, body composition studies, and aging research. At therapeutic doses, it consistently improves lean mass, reduces visceral adiposity, and enhances recovery. The key variable is dose — the protocol uses conservative wellness doses (2 IU/day) well below the supraphysiologic ranges associated with adverse effects.

Mechanism of Action

Semax is a synthetic heptapeptide analog of ACTH(4-10), the fragment of adrenocorticotropic hormone responsible for its nootropic effects without its adrenal-stimulating activity. It increases BDNF (brain-derived neurotrophic factor) expression in the hippocampus and prefrontal cortex, enhances dopaminergic and serotonergic neurotransmission, and exhibits potent neuroprotective effects against ischemic and oxidative stress. Intranasal administration achieves direct CNS delivery via the olfactory pathway, bypassing the blood-brain barrier.

Research Summary

Semax has been approved as a pharmaceutical drug in Russia since 1994 and is used clinically for stroke recovery, cognitive impairment, and ADHD. Multiple randomized controlled trials have demonstrated improvements in attention, memory consolidation, and executive function. Its BDNF-upregulating mechanism makes it particularly relevant for high-cognitive-load professionals.

Mechanism of Action

Selank is a synthetic analog of the endogenous immunomodulatory peptide tuftsin. It modulates GABAergic neurotransmission (similar mechanism to benzodiazepines but without receptor downregulation or dependency), enhances serotonin metabolism, and regulates expression of IL-6, IL-1β, and other pro-inflammatory cytokines. The net effect is anxiolysis without sedation — reduced cortisol interference during high-stakes cognitive tasks while maintaining full alertness and executive function.

Research Summary

Selank has been approved as a pharmaceutical in Russia since 2009 for anxiety and asthenic conditions. Clinical trials demonstrate anxiolytic efficacy comparable to benzodiazepines without sedation, tolerance, or withdrawal. Its dual action on cognitive performance and immune modulation makes it uniquely suited to high-stress professional environments.

Mechanism of Action

Retatrutide is a first-in-class triple receptor agonist targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously. GLP-1 agonism suppresses appetite and slows gastric emptying. GIP agonism enhances insulin secretion and improves adipose tissue metabolism. Glucagon receptor agonism — the differentiating mechanism — directly stimulates hepatic lipolysis and increases energy expenditure, producing fat loss that exceeds any single or dual incretin agonist. The combination drives aggressive body recomposition while preserving lean mass.

Research Summary

Retatrutide is the most potent body composition agent in clinical development. Phase II trials published in the New England Journal of Medicine demonstrated 24.2% mean body weight reduction at 48 weeks — the largest weight loss ever recorded in a pharmaceutical trial. Phase III trials are ongoing. Its triple-receptor mechanism produces fat loss substantially exceeding semaglutide (GLP-1 only) or tirzepatide (GIP/GLP-1 dual).